pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2017-27-6-811-815pulmo-949Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯCLINICAL PHARMACOLOGYПрименение N-aцетилцистеина у детей: современные данные и новые возможностиN-acetylcysteine in children: current data and novel opportunitiesДроновИ. А.DronovI. A.

Дронов Иван Анатольевич – кандидат медицинских наук, доцент кафедры детских болезней лечебного факультета, врач-клинический фармаколог Университетской детской клинической больницы 

119991, Москва, ул. Трубецкая, 8, стр. 2

Ivan A. Dronov, Candidate of Medicine, Associate Professor, Department of Pediatric Diseases, Therapeutic Faculty, clinical pharmacologist, University Pediatric Teaching Hospital 

Trubetskaya ul. 8, build. 2, Moscow, 119991, Russia

dronow@yandex.ruШахназароваМ. Д.ShakhnazarovaM. D.

Шахназарова Марина Далгатовна – кандидат медицинских наук, доцент кафедры детских болезней лечебного факультета 

119991, Москва, ул. Трубецкая, 8, стр. 2

Marina D. Shakhnazarova, Candidate of Medicine, Associate Professor, Department of Pediatric Diseases, Therapeutic Faculty 

Trubetskaya ul. 8, build. 2, Moscow, 119991, Russia

marinashakh@mail.ruФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияI.M.Sechenov First Moscow State Medical University, Healthcare Ministry of RussiaRussian Federation201723022018276811815Copyright © Дронов И.А., Шахназарова М.Д., 20182018Дронов И.А., Шахназарова М.Д.Dronov I.A., Shakhnazarova M.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/949

Рациональный выбор эффективного и безопасного муколитического препарата среди множества разжижающих мокроту средств является актуальным вопросом, особенно в педиатрии. В статье представлены современные данные об оценке применения N-ацетилцистеина (NAC) в лечении инфекций верхних и нижних дыхательных путей у детей. По результатам рандомизированных контролируемых исследований подтверждены выраженный муколитический эффект препарата без избыточного увеличения объема мокроты («заболачивания» легких) и его безопасность у детей старше 2 лет. По сравнению с другими муколитическими препаратами, NAC обладает дополнительными терапевтическим эффектами – антиоксидантным, антитоксическим (в частности, при отравлении ацетаминофеном), способностью не только разрушать бактериальные биопленки, но и препятствовать их образованию. Оригинальный препарат NAC (Флуимуцил®) выпускается в различных лекарственных формах – гранул для приготовления раствора для приема внутрь, шипучих таблеток, раствора для инъекций и ингаляций, а с 2016 г. – в виде раствора для приема внутрь для детей от 2 лет, удобного в дозировании в педиатрической практике.

The optimal choice of effective and safe mucolytic drug is an important issue, especially in pediatric practice. A role of N-acetylcysteine (NAC) for treatment of upper and lower respiratory infections in children has been discussed in this review. Randomised controlled trials confirmed significant mucolytic effect and safety of NAC in children > 2 years old without excessive increase in bronchorrhea. Compared to other mucolytics NAC has additional therapeutic properties such as antioxidant and antitoxic (particularly, in paracetamol poisoning). NAC could destroy bacterial biofilms and prevent their occurrence. Original NAC (Fluimucil®) is available in different drug formulations: granules and tablets for oral solution, solution for inhalation and parenteral use. Since 2016, Fluimucil has been available as oral solution for children ≥ 2 years old with ease dosing.

N-aцетилцистеинФлуимуцил®муколитические препаратыдетипарацетамолинфекции дыхательных путейN-acetylcysteineFluimucil®mucolytic agentschildrenparacetamolrespiratory infectionsReferencesSuddarth S.B. Acetylcysteine, a new and effective mucolytic agent. Bull. Geisinger. 1963; 15: 65–69.Suddarth S.B. Acetylcysteine, a new and effective mucolytic agent. Bull. Geisinger. 1963; 15: 65–69.Геппе Н.А., Малахов А.Б. Муколитические и противокашлевые средства в практике педиатра (лекция). Детский доктор. 1999; (4): 42–45Geppe N.A., Malakhov A.B. Mucolytic and antitussive agents in pediatric practice (a lection). Detskiy doktor. 1999; (4): 42–45 (in Russian).Морозова Т.Е., Андрущишина Т.Б. Ацетилцистеин в клинической практике. Врач. 2007; (12): 37–38.Morozova T.E., Andrushchishina T.B. Acetylcysteine in clinical practice. Vrach. 2007; (12): 37–38 (in Russian).Chalumeau M., Duijvestijn Y.C. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst. Rev. 2013; (5): CD003124. DOI: 10.1002/14651858.CD003124.pub4.Chalumeau M., Duijvestijn Y.C. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst. Rev. 2013; (5): CD003124. DOI: 10.1002/14651858.CD003124.pub4.Чикина С.Ю., Чучалин А.Г. N-ацетилцистеин: все ли возможности мы используем? Атмосфера. Пульмонология и аллергология. 2013; (1): 20–26.US National Library of Medicine National Institutes of Health. Available at: www.ncbi.nlm.nih.gov/pubmed/ [Accessed 19.11.2017] (внутритекстовая ссылка!)Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 1989; 6 (6): 593-597. DOI: 10.1016/0891-5849(89)90066-X.Chikina S.Yu., Chuchalin A.G. N-acetylcysteine: do we use all opportunities? Atmosfera. Pul'monologiya i allergologiya. 2013; (1): 20–26 (in Russian).Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343 (4): 269–280. DOI: 10.1056/NEJM200007273430407Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 1989; 6 (6): 593–597. DOI: 10.1016/0891-5849(89)90066-X.Yoon E., Babar A., Choudhary M. et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J. Clin. Transl. Hepatol. 2016; 4 (2): 131–142. DOI: 10.14218/JCTH.2015.00052.Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343 (4): 269–280. DOI: 10.1056/NEJM200007273430407Савьюк Ф., Данель В., Зобнин Ю.В. Острое отравление парацетамолом: неотложная помощь. Сибирский медицинский журнал. 2008; (6): 107–111.Yoon E., Babar A., Choudhary M. et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J. Clin. Transl. Hepatol. 2016; 4 (2): 131–142. DOI: 10.14218/JCTH.2015.00052.Jaeschke H. Acetaminophen: dose-dependent drug hepatotoxicity and acute liver failure in patients. Dig. Dis. 2015; 33 (4): 464–471. DOI: 10.1159/000374090.Sav'yuk F., Danel' V., Zobnin Yu.V. Acute paracetamol poisoning: a rescue treatment. Sibirskiy meditsinskiy zhurnal. 2008; (6): 107–111 (in Russian).American Academy of Pediatrics. Committee on Drugs. Acetaminophen toxicity in children. Pediatrics. 2001; 108 (4): 1020–1024. DOI: 10.1542/peds.108.4.1020.Jaeschke H. Acetaminophen: dose-dependent drug hepatotoxicity and acute liver failure in patients. Dig. Dis. 2015; 33 (4): 464–471. DOI: 10.1159/000374090.Heard K.J. Acetylcysteine for acetaminophen poisoning. N. Engl. J. Med. 2008; 359 (3): 285–292. DOI: 10.1056/NEJMct0708278.American Academy of Pediatrics. Committee on Drugs. Acetaminophen toxicity in children. Pediatrics. 2001; 108 (4): 1020–1024. DOI: 10.1542/peds.108.4.1020.Smilkstein M.J., Knapp G.L., Kulig K.W., Rumack B.H. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N. Engl. J. Med. 1988; 319 (24): 1557–1562. DOI: 10.1056/NEJM198812153192401.Heard K.J. Acetylcysteine for acetaminophen poisoning. N. Engl. J. Med. 2008; 359 (3): 285–292. DOI: 10.1056/NEJMct0708278.Brok J., Buckley N., Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst. Rev. 2006; (2): CD003328. DOI: 10.1002/14651858.CD003328.pub2.Smilkstein M.J., Knapp G.L., Kulig K.W., Rumack B.H. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N. Engl. J. Med. 1988; 319 (24): 1557–1562. DOI: 10.1056/NEJM198812153192401.Mehrpour O., Ballali-Mood M. Why not formulate an acetaminophen tablet containing N-acetylcysteine to prevent poisoning? J. Med. Toxicol. 2011; 7 (1): 95–96. DOI: 10.1007/s13181-010-0126-2.Brok J., Buckley N., Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst. Rev. 2006; (2): CD003328. DOI: 10.1002/14651858.CD003328.pub2.El-Ebiary A.A., Elsharkawy R.E., Soliman N.A. et al. N-acetylcysteine in acute organophosphorus pesticide poisoning: a randomized, clinical trial. Basic. Clin. Pharmacol. Toxicol. 2016; 119 (2): 222–227. DOI: 10.1111/bcpt.12554.Mehrpour O., Ballali-Mood M. Why not formulate an acetaminophen tablet containing N-acetylcysteine to prevent poisoning? J. Med. Toxicol. 2011; 7 (1): 95–96. DOI: 10.1007/s13181-010-0126-2.Tehrani H., Halvaie Z., Shadnia S. et al. Protective effects of N-acetylcysteine on aluminum phosphide-induced oxidative stress in acute human poisoning. Clin. Toxicol. (Phila.). 2013; 51 (1): 23–28. DOI: 10.3109/15563650.2012.743029.El-Ebiary A.A., Elsharkawy R.E., Soliman N.A. et al. N-acetylcysteine in acute organophosphorus pesticide poisoning: a randomized, clinical trial. Basic. Clin. Pharmacol. Toxicol. 2016; 119 (2): 222–227. DOI: 10.1111/bcpt.12554.Montanini S., Sinardi D., Praticò C. et al. Use of acetylcysteine as the life-saving antidote in Amanita phalloides (death cap) poisoning. Case report on 11 patients. Arzneimittelforschung. 1999; 49 (12): 1044–1047.Tehrani H., Halvaie Z., Shadnia S. et al. Protective effects of N-acetylcysteine on aluminum phosphide-induced oxidative stress in acute human poisoning. Clin. Toxicol. (Phila.). 2013; 51 (1): 23–28. DOI: 10.3109/15563650.2012.743029.Kasperczyk S., Dobrakowski M., Kasperczyk A. et al. Effect of N-acetylcysteine administration on homocysteine level, oxidative damage to proteins, and levels of iron (Fe) and Fe-related proteins in lead-exposed workers. Toxicol. Ind. Health. 2016; 32 (9): 1607–1618. DOI: 10.1177/0748233715571152.Montanini S., Sinardi D., Praticò C. et al. Use of acetylcysteine as the life-saving antidote in Amanita phalloides (death cap) poisoning. Case report on 11 patients. Arzneimittelforschung. 1999; 49 (12): 1044–1047.Baniasadi S., Eftekhari P., Tabarsi P. et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur. J. Gastroenterol. Hepatol. 2010; 22 (10): 1235–1238. DOI: 10.1097/MEG.0b013e32833aa11b.Kasperczyk S., Dobrakowski M., Kasperczyk A. et al. Effect of N-acetylcysteine administration on homocysteine level, oxidative damage to proteins, and levels of iron (Fe) and Fe-related proteins in lead-exposed workers. Toxicol. Ind. Health. 2016; 32 (9): 1607–1618. DOI: 10.1177/0748233715571152.Karimzadeh I., Khalili H., Sagheb M.M., Farsaei S. A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity. Expert Opin. Drug Metab. Toxicol. 2015; 11 (9): 1345–1355. DOI: 10.1517/17425255.2015.1042363.Baniasadi S., Eftekhari P., Tabarsi P. et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur. J. Gastroenterol. Hepatol. 2010; 22 (10): 1235–1238. DOI: 10.1097/MEG.0b013e32833aa11b.Kocyigit I., Vural A., Unal A. et al. Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis. Eur. Arch. Otorhinolaryngol. 2015; 272 (10): 2611–2620. DOI: 10.1007/s00405-014-3207-z.Karimzadeh I., Khalili H., Sagheb M.M., Farsaei S. A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity. Expert Opin. Drug Metab. Toxicol. 2015; 11 (9): 1345–1355. DOI: 10.1517/17425255.2015.1042363.Feldman L., Efrati S., Eviatar E. et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007; 72 (3): 359–363. DOI: 10.1038/sj.ki.5002295.Kocyigit I., Vural A., Unal A. et al. Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis. Eur. Arch. Otorhinolaryngol. 2015; 272 (10): 2611–2620. DOI: 10.1007/s00405-014-3207-z.Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 2016; 117: 190–197. DOI: 10.1016/j.rmed.2016.06.015.Feldman L., Efrati S., Eviatar E. et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007; 72 (3): 359–363. DOI: 10.1038/sj.ki.5002295.Domenech M., García E. N-acetyl-cysteine and cysteamine as new strategies against mixed biofilms of nonencapsulated Streptococcus pneumoniae and nontypeable Haemophilus influenza. Antimicrob. Agents Chemother. 2017; 61 (2): e01992-16. DOI: 10.1128/AAC.01992-16.Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 2016; 117: 190–197. DOI: 10.1016/j.rmed.2016.06.015.Dinicola S., De Grazia S., Carlomagno G., Pintucci J.P. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur. Rev. Med. Pharmacol. Sci. 2014; 18 (19): 2942–2948.Domenech M., García E. N-acetyl-cysteine and cysteamine as new strategies against mixed biofilms of nonencapsulated Streptococcus pneumoniae and nontypeable Haemophilus influenza. Antimicrob. Agents Chemother. 2017; 61 (2): e01992-16. DOI: 10.1128/AAC.01992-16.Leite B, Gomes F, Teixeira P. et al. Staphylococcus epidermidis biofilms control by N-acetylcysteine and rifampicin. Am. J. Ther. 2013; 20 (4): 322–328. DOI: 10.1097/MJT.0b013e318209e17b.Dinicola S., De Grazia S., Carlomagno G., Pintucci J.P. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur. Rev. Med. Pharmacol. Sci. 2014; 18 (19): 2942–2948.Macchi A., Ardito F., Marchese A. et al. Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms. J. Chemother. 2006; 18 (5): 507–513. DOI: 10.1179/joc.2006.18.5.507.Leite B, Gomes F, Teixeira P. et al. Staphylococcus epidermidis biofilms control by N-acetylcysteine and rifampicin. Am. J. Ther. 2013; 20 (4): 322–328. DOI: 10.1097/MJT.0b013e318209e17b.Babić I., Baudoin T., Trotić R., Bedeković V. Therapeutic efficacy of azithromycin and acetylcysteine in chronic otitis media with effusion. Eur. Arch. Otorhinolaryngol. 2017; 274 (3): 1351–1356. DOI: 10.1007/s00405-016-4389-3.Macchi A., Ardito F., Marchese A. et al. Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms. J. Chemother. 2006; 18 (5): 507–513. DOI: 10.1179/joc.2006.18.5.507.Babić I., Baudoin T., Trotić R., Bedeković V. Therapeutic efficacy of azithromycin and acetylcysteine in chronic otitis media with effusion. Eur. Arch. Otorhinolaryngol. 2017; 274 (3): 1351–1356. DOI: 10.1007/s00405-016-4389-3.Babić I., Baudoin T., Trotić R., Bedeković V. Therapeutic efficacy of azithromycin and acetylcysteine in chronic otitis media with effusion. Eur. Arch. Otorhinolaryngol. 2017; 274 (3): 1351–1356. DOI: 10.1007/s00405-016-4389-3.

The authors declare that there are no conflicts of interest present.